Munguva pfupi yapfuura, Bayer yakazivisa kuti National Medical Products Administration (NMPA) yeChina yakabvumidza mushonga mutsva we sevabertinib wekurapa varwere vakuru vane kenza yemapapu isingarapike munharaunda kana kuti inopararira isina masero madiki (NSCLC) vane HER2 (ERBB2) inomutsa shanduko uye vakambosangana nekufambira mberi kwechirwere mushure mekurapwa kamwe chete kare.
Izvi zvinoreva kuti zvisinei nekuti unobva kunyika ipi, ikozvino unogona kuwana iyi nzira yekurapa yemhando yepamusoro yepasi rose kuburikidza neBeijing South Region Oncology Hospital International Department.
Sevabertinib: Kunyatsotarisa HER2 mutations
Sevabertinib mushonga mutsva, unonwiwa, unodzoserwa, unodzivirira HER2 ine mamorekuru madiki (kusanganisira HER2 exon 20 insertions uye point mutations) pamwe neEGFR. Kana ichienzaniswa neTKI dzechinyakare dzisingadzoreki, TKI inodzoserwa inopa kuvharirwa kwenguva pfupi uye kwakarurama kwechinangwa, zvichiita kuti kurapwa kuve kwakanyatsodzorwa uye zvingangoderedza migumisiro yenguva refu.
Kukurudzira Ruzivo rweKliniki: Mhinduro Dzakakosha, Mabhenefiti Anogara Nguva refu
Kubvumidzwa kwesevabertinib kwakavakirwa pamhedzisiro yakanaka kubva mukuyedzwa kwepasi rose kwechikamu chepakati penyika chePhase I/II SOHO-01:
- Muvarwere vasina kumbobvira vagamuchira kurapwa kweHER2-targeted ADC
Muyero wekupindura wakanangana (ORR) wakasvika 64%, kusanganisira mhinduro dzakakwana 2.5% uye mhinduro dzisina kukwana 62%. Nguva yepakati yekupindura yaive mwedzi 9.2.
- Muvarwere vakambogamuchira kurapwa kweADC kwakanangana neHER2
ORR yaive ichiri 38%, kusanganisira mhinduro dzakakwana dze5.5% uye mhinduro dzisina kukwana dze33%. Nguva yepakati yemhinduro yaive mwedzi minomwe.
Kuchengetedzwa kwenyaya iyi kunokwanisika uye kunoenderana nemishumo yapfuura, zvichipa hwaro hwakavimbika hwekurapwa kwenguva refu.
Sei Uchifanira Kusarudza Dhipatimendi Repasirose reBeijing South Region Oncology Hospital?
Senzvimbo yekurapa yepasi rose yakatarisana nekutarisira kenza nenzira chaiyo, tinopa varwere vepasi rose:
- Chikwata chekurapa chine mitauro yakawanda: Masevhisi muChinese, Chirungu, ChiRussian, ChiArabic, nezvimwewo, zvichiita kuti kutaurirana kuve nyore.
- Mabasa evarwere vepasi rose anoitirwa vanhu vose: Kurongeka kwakazvipira kubva pakubvunzana vari kure uye rubatsiro rwevhiza yekurapa kusvika pakuendeswa kunhandare yendege, kuronga kwekuiswa muchipatara, uye kuteverwa mushure mekurapwa.
- Zvirongwa zvekurapa zvakagadzirirwa munhu: Kurapa kwakagadzirirwa munhu wacho uye zvirongwa zvakakwana zvekurapa zvichibva pamajini emurwere uye mamiriro ake ezvinhu.
Taura Nesu Nhasi Kuti Utange Rwendo Rwako rweTariro
Dhipatimendi rePasirose reChipatara cheOncology cheBeijing South Region
Nhare yeGlobal Patient Hotline: 400-880-3716
WeChat: 17801183037
Tsamba yemagetsi:
- 100085_010@163.com
- myimmnet@163.com
—
Hupenyu Hwako Hunofanirwa Kurapwa Kwakanakisisa
Ungave uchitsvaga tariro yekutanga kana kuti watofambira mberi mushure mekurapwa kakawanda, sevabertinib inogona kupa shanduko huru isati yamboitika. Dhipatimendi reBeijing South Region Oncology Hospital International rakagadzirira kukuvhurira nzira yekurapa—fonera 400-880-3716 izvozvi, kana kutibata nesu kuburikidza neWeChat kana email. Ngatikubatsirei kubatana nenyanzvi dzinotungamira, kuongorora kukodzera kwako, uye kuronga rwendo rwako rwekurapwa muChina.
Usamirire. Kufona kwese kunogona kuva kutanga kutsva.
Dhipatimendi reInternational Hospital Oncology reBeijing South Region — Rinobatanidza Varwere Vepasi Pose neChina's Precision Medicine.
Nguva yekutumira: Kubvumbi-16-2026